|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|
| Assets | |||||
| Investments at fair value | |||||
| Cash | |||||
| Interest and fees receivable | |||||
| Deferred financing costs | |||||
| Due from advisor | |||||
| Total assets | |||||
| Liabilities | |||||
| Repurchase agreements | |||||
| Interest Payable | |||||
| Directors’ fees payable | |||||
| Accrued administration fees | |||||
| Accrued organizational costs | |||||
| Accrued offering costs | |||||
| Accrued incentive fees | |||||
| Distribution payable | |||||
| Other payable | |||||
| Total liabilities | |||||
| Redeemable Series A Cumulative Preferred Shares, $0.001 par value, 125 shares authorized; 125 issued and outstanding as of June 30, 2025, and none issued and outstanding as of December 31, 2024, net of offering costs | |||||
| Total net assets applicable to common shareholders | |||||
| Total liabilities, redeemable preferred shares and net assets applicable to common shareholders | |||||
| Net asset value per share applicable to common shares (in dollars per share) | |||||
| Net assets applicable to common shareholders | |||||
| Common Shares, $0.001 par value, unlimited shares authorized, 20,167,474 and 13,583,897 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | |||||
| Paid-in-capital in excess of par value | |||||
| Distributable earnings (loss) |
Loading...
